Patents by Inventor Wanda Kay O'Neal

Wanda Kay O'Neal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of MTAP inhibitors for the treatment of lung disease
    Patent number: 10918641
    Abstract: This invention relates generally to the use of 5?-methylthioadenosine phosphorylase (MTAP) inhibitors for the treatment of lung diseases associated with inflammation, such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Small molecule inhibitors of MTAP can sustain accumulation of endogenous MTA to therapeutically beneficial levels resulting in decreased inflammation in CF and COPD.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: February 16, 2021
    Assignees: The University of North Carolina at Chapel Hill, Albert Einstein College of Medicine, Inc., Victoria Link Limited
    Inventors: Charles R. Esther, Jr., Michael R. Knowles, Wanda Kay O'Neal, Deepika Polineni, Steven Isaacman, Andrew B. Mahon
  • Use of MTAP Inhibitors for the Treatment of Lung Disease
    Publication number: 20180353511
    Abstract: This invention relates generally to the use of 5?-methylthioadenosine phosphorylase (MTAP) inhibitors for the treatment of lung diseases associated with inflammation, such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Small molecule inhibitors of MTAP can sustain accumulation of endogenous MTA to therapeutically beneficial levels resulting in decreased inflammation in CF and COPD.
    Type: Application
    Filed: April 3, 2018
    Publication date: December 13, 2018
    Inventors: Charles R. Esther, JR., Michael R. Knowles, Wanda Kay O'Neal, Deepika Polineni, Steven Isaacman, Andrew B. Mahon